Bright Minds announces that its collaborating with Firefly Neuroscience to provide a full analysis of EEG data in the BREAKTHROUGH study. Bright Minds stock soared 1,445% in a single day last week ...

Piper Sandler analyst Yasmeen Rahimi initiated coverage with a Buy rating on Bright Minds Biosciences (DRUG – Research Report) today and set a price target of $93.00. The company’s shares ...

“We are fortunate to welcome these accomplished and highly respected researchers to the Bright Minds team at this exciting juncture. As we advance our clinical programs through the regulatory ...

Bright Minds Biosciences (DRUG) is finishing 2024 as one of the best-performing small-cap stocks, posting a remarkable 2400% increase in the share price in the last quarter. News of the firm’s ...

At the request of CIRO, Bright Minds Biosciences Inc. wishes to confirm that the Company's management is unaware of any material changes in the Company's operations that would account for the ...

NEW YORK and VANCOUVER, British Columbia, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company ...